Recurrent bladder cancer can be detected through measuring a certain protein present in the urine. Where the US is concerned, bladder cancer is reported to be the fifth most malignant, which recorded 63,210 new cases in the year 2005 //year alone, with over 13,000 deaths. The country has a total of 500,000 patients with a bladder cancer history, and the chances of its recurrence is between 50% and 90%.
There is no known procedure of monitoring this ailment which is 100% perfect. The standard approach is the cystoscopy approach. The cytologic (cell) analysis has a reputation for variability and poor sensitivity while interpreting results. A noninvasive urine test’s clinical utility was examined by the Anderson Cancer Center’s H. Barton Grossman. This is a test for the protein NMP22 which helps in detecting recurrent cancer.
The study involved 668 patients who had a history of the ailment. The urine samples were tested for the NMP22 protein before the cystoscopy. As many as 103 bladder cancer cases were identified, and 91.3% of them were identified by cystoscopy. When cystoscopy was combined with NMP22, about 99% of the malignancies were detected, thus proving the efficacy of the combination.
'"/>Page: 1 Related medicine news :1.
Measuring Death Risk in COPD Patients2.
Measuring Exercise Capacity To Predict Heart Disease3.
A Novel Method For Measuring Interstitial Fluid Pressure In Cancer Tissues 4.
Measuring disseminated cancer cells in bone marrow - valuable tool for detecting early breast cancer metastasis5.
New Method For Measuring Dyskinesia In Parkinsons Being Developed6.
Measuring the Quantity of Information Passed on From the Eye to the Brain7.
Measuring Calcium Intake Help to Identify Osteoporosis in Prostate Cancer Patient8.
PCR emerging as a promising technique for Diagnosing Urinary Tuberculosis9.
A better test than cytology for Urinary Malignancy 10.
Once-Daily Cipro(R) XR for Treating Complicated Urinary Tract Infections11.
Urinary Incontinence May Be Hereditary